Novel Small Molecule MEK Inhibitor URML-3881 Enhances Cisplatin Sensitivity in Clear Cell Ovarian Cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Advanced clear cell ovarian cancer (CCOC) is a deadly malignancy with limited treatment options.
• CCOC exhibits inherent chemotherapy resistance, partly due to prosurvival signaling pathways like MAPK.
• Elevated MAPK activity is observed in CCOC and increases with cisplatin exposure.

Purpose of the Study:

• To investigate the efficacy of a novel MEK inhibitor, URML-3881, in treating CCOC.
• To evaluate the combination of MEK inhibition and cisplatin as a therapeutic strategy for CCOC.

Main Methods:

• In vitro assessment of URML-3881 on CCOC cell viability, apoptosis, and proliferation.
• In vivo studies evaluating tumor regression with URML-3881, cisplatin, and their combination.
• Analysis of MAPK pathway activity in response to treatment.

Main Results:

• URML-3881 reduced in vitro CCOC viability by inducing apoptosis and inhibiting proliferation.
• Neither URML-3881 nor cisplatin alone significantly regressed tumors in vivo.
• The combination of URML-3881 and cisplatin resulted in significant and prolonged in vivo tumor regression.

Conclusions:

• MEK inhibition combined with cisplatin is a superior treatment strategy for CCOC compared to monotherapy.
• This combination therapy warrants further investigation in preclinical and clinical settings for CCOC treatment.